Opinion|Videos|October 8, 2024
Overview of DAPA ECHO Trial
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- The DAPA ECHO trial focused on dapagliflozin's effects on myocardial performance in nondiabetic heart failure patients.
- A randomized, double-blind, placebo-controlled design was employed, using echocardiography to assess cardiac function.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 for the DAPA ECHO trial in which the effects of dapagliflozin on myocardial performance were studied in patients with nondiabetic heart failure.
- What was the objective of this analysis?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. What are the key clinical implications in using dapagliflozin in patients with nondiabetic heart failure?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices
2
Immune Checkpoint Inhibitors Safe to Use for NSCLC in Patients With HIV
3
CMS Announces GENEROUS Model to Lower Medicaid Drug Prices
4
Medicare Advantage Reimbursement Structures Impact Home Health Delivery and Outcomes
5
